Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




FDA Clearance for New Oncological Imaging Analytics Software

By MedImaging International staff writers
Posted on 21 Feb 2016
A new analytics software package intended to increase radiologists' workflow efficiencies for oncological cases, and advanced decision support has received US Food and Drug Administration (FDA) 510(k) clearance.

The software package features a quantitative imaging dashboard with time-sequenced Electronic Health Record (EHR) information, image characterization, and image tracking. More...
Another feature is the ability to track a tumor or nodule over multiple, spatially registered imaging exams to show whether the cancer is stable, shrinking, or growing. Visualizing changes in the structure of cancers is important for monitoring and/or adjusting the treatment regime of a patient.

The imaging analytics package was developed by HealthMyne (Madison, WI, USA), a company that provides imaging informatics data mining solutions, and solutions for automating data capture, and structured reporting. EHR information on the software dashboard is provided by Epic Systems (Verona, Wisconsin, USA).

The HealthMyne software can be used for automatic identification of nodule growth in lung cancer screening programs, which provides an indication of potential malignancy of a nodule, and additional follow-up treatment that may be necessary. In addition, in view of the large increase in the number of cancer treatment options available today, the HealthMyne package can be used to provide quantitative insight and improve clinical decision-making.

Roger Chylla, CTO of HealthMyne, said, “By automatically delineating the boundaries of a lung nodule (or tumor), our software can make other sophisticated measurements within those boundaries - such as quantitatively describing important properties like size, shape, and texture. Physicians can examine these properties to make critical judgments about a patient’s prognosis, follow-up schedule, or how to best treat them.”

Related Links:

HealthMyne
Epic Systems



MRI System
nanoScan MRI 3T/7T
Digital Radiographic System
OMNERA 300M
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
40/80-Slice CT System
uCT 528
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Nuclear Medicine

view channel
Image: The new tracer, 64Cu-NOTA-EV-F(ab′)2​, targets nectin-4, a protein strongly linked to tumor growth in both TNBC and UBC cancer types. (Wenpeng Huang et al., DOI: 10.2967/jnumed.125.270132)

PET Tracer Enables Same-Day Imaging of Triple-Negative Breast and Urothelial Cancers

Triple-negative breast cancer (TNBC) and urothelial bladder carcinoma (UBC) are aggressive cancers often diagnosed at advanced stages, leaving limited time for effective treatment decisions.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.